6640--Cost-Per-Test RT-PCR RSV Infections RFQ 36C25225Q0249 Posted Sources Sought under 36C25225Q0226

Closed Solicitation Posted

This opportunity was awarded. See the award notice from .

Solicitation number
36C25225Q0249
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Notice details come from SAM.gov. Updated .

About this opportunity

The Department of Veterans Affairs Veterans Health Administration is seeking FDA-approved or EUA-authorized, CLIA-waived rapid PCR-based point of care analyzers and assays for simultaneous detection of SARS-CoV-2, RSV, and Influenza A & B viruses in nasal swab specimens. This solicitation, identified as RFQ 36C25225Q0249, requires instruments with specific technical capabilities including a compact one cubic foot footprint, 30-minute result production, and interface compatibility with RALS middleware and VA electronic health records. The VA will evaluate quotes using a comparative process that considers both technical capability and price, with the flexibility to select a quote that provides additional benefits beyond the lowest price. The solicitation is unrestricted under NAICS code 334516 with a size standard of 1,000 employees. Interested vendors must submit their responses by February 21, 2025, at 12:00 CST.

The contract will be a single-award, firm-fixed price Indefinite Delivery/Indefinite Quantity (IDIQ) agreement with five one-year ordering periods. The minimum contract guarantee is $50,000, with a maximum ceiling amount of $800,000. Eight instruments will be deployed to VA facilities located in Michigan and Wisconsin, focusing on point-of-care diagnostic testing capabilities. The procurement requires vendors to provide analyzers with minimal sample manipulation requirements and secure data management features. This solicitation represents a significant opportunity for manufacturers of analytical laboratory instruments to support critical healthcare diagnostics within the Veterans Health Administration network, with potential for substantial recurring revenue through the multi-year contract structure.

Notice text

Cost per test requirement for FDA-approved or authorized by FDA under an EUA, CLIA-waived, rapid, PCR based, interfaced, point of care analyzers and assays for each of the following: detection of SARS-CoV-2, RSV, and Influenza A & B viruses simultaneously in a nasal swab specimen.

Files

File Type Posted
36C25225Q0249.docx DOCX document

Notice history

Notice Type Posted
6640--Cost-Per-Test RT-PCR RSV Infections RFQ 36C25225Q0249 Posted Sources Sought under 36C25225Q0226 Award Award Notice
This notice Latest solicitation Solicitation
6640--Cost-Per-Test RT-PCR RSV Infections RFQ 36C25225Q0249 Posted Sources Sought under 36C25225Q0226 Original Pre-Solicitation

Similar open opportunities

Opportunity Agency Set-aside Responses due
6550-- Roche Ventana Reagents IDIQ 5 Successive 1 Year Delivery Orders Slvhcs New Orleans, Louisiana 70119, United States · NAICS 325413 Veterans Integrated Service Network 16 No set-aside
6550--Cepheid GeneXpert Testing Supplies Beckley Vamc Clarksburg Vamc Vamhcs Washington Vamc · NAICS 325413 Veterans Integrated Service Network 5 No set-aside
Purchase of Rapid Syndromic Molecular Testing Reagents for Seattle VAMC Seattle, Washington 98108, United States · NAICS 325413 Veterans Integrated Service Network 20 No set-aside
6550--VISN 4 Coagulation Testing Pittsburgh, Pennsylvania 15215, United States · NAICS 334516 Veterans Integrated Service Network 4 No set-aside
RFP-797-FSS-03-0001-R1: 66III Cost-Per-Test, Clinical Laboratory Analyzer United States · NAICS 334516 Veterans Integrated Service Network 12 No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors